Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Juniper Pharmaceuticals
Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.
AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.
Gilead’s tie-up with Google’s Verily will explore the immunological underpinnings of rheumatoid arthritis, lupus and GI disorders. Janssen acquires BeneVir and its oncolytic virus expertise, while United Therapeutics buys out SteadyMed.
Iterum Therapeutics and Genoa Pharmaceuticals topped the list of biopharmaceutical start-up firms closing new venture capital rounds in May with $65m and $62m, respectively, to advance drug candidates for bacterial infections and idiopathic pulmonary fibrosis.
- Contract Research, Toxicology Testing-CRO
- Controlled Release
- Topical Delivery
- Drug Delivery
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Molecular Profiles Ltd.
- Columbia Laboratories, Inc.
- Juniper Pharma Services